Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Myc family transcription factors are implicated in cancer development, including prostate cancer (PCa).
• Resistance to androgen receptor (AR)-targeted therapies can lead to lethal neuroendocrine prostate cancer (NEPC), marked by N-Myc overexpression.
• Currently, no approved treatments exist for NEPC, resulting in poor patient outcomes.

Purpose of the Study:

• To investigate the N-Myc-Max DNA binding domain (DBD) as a therapeutic target for NEPC.
• To discover novel small molecule inhibitors against N-Myc using computer-aided drug design (CADD).

Main Methods:

• Utilized computer-aided drug design (CADD) to identify potential inhibitors of the N-Myc-Max DBD.
• Screened and optimized compounds for anti-N-Myc potency and antiproliferative activity.

Main Results:

• Identified a compound, VPC-70619, demonstrating significant potency against N-Myc.
• VPC-70619 exhibited strong antiproliferative effects on N-Myc-expressing cell lines, including those representative of NEPC.

Conclusions:

• The N-Myc-Max DBD is a viable target for NEPC therapy.
• VPC-70619 represents a promising lead compound for developing new treatments for NEPC.
• Further development of VPC-70619 could address the unmet need for effective NEPC therapies.